Tech Company Financing Transactions

OncoResponse Funding Round

On 9/12/2018, OncoResponse received $40 million in Series B funding from RiverVest Venture Partners, Alexandria Venture Investments and Arch Venture Partners.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series B
Proceeds Purpose
The proceeds will be used to advance the company's five drug candidates into preclinical and clinical development.

Company Information

Company Status
Private & Independent
Mailing Address
1124 Columbia St. 300
Seattle, WA 98104
Email Address
OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery.
OncoResponse LinkedIn Company Profile
Social Media
OncoResponse Company Twitter Account
Company News
OncoResponse News
OncoResponse on Facebook
OncoResponse on YouTube

Management Team

Email & Social
Chief Executive Officer
Clifford Stocks
  Clifford Stocks LinkedIn Profile  Clifford Stocks Twitter Account  Clifford Stocks News  Clifford Stocks on Facebook
Chief Medical Officer
Robert Lechleider
  Robert Lechleider LinkedIn Profile  Robert Lechleider Twitter Account  Robert Lechleider News  Robert Lechleider on Facebook
Chief Scientific Officer
Kamal Puri
  Kamal Puri LinkedIn Profile  Kamal Puri Twitter Account  Kamal Puri News  Kamal Puri on Facebook



Browse more venture capital transactions:

Prev: 9/12/2018: PingCAP venture capital transaction
Next: 9/12/2018: Momentum IoT venture capital transaction


Share this article


About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary